Pulmonary toxicity of alpha tumor necrosis factor in patients treated by isolation perfusion.
We studied pulmonary function in 22 patients affected by in-transit metastases from cutaneous melanoma and metastases from soft tissue sarcoma of the limbs who were treated with isolation perfusion in extracorporeal circulation with rTNF alpha at doses ranging from 0.5 to 4 mg/m2 in mild hyperthermia. Seventeen patients suffered from respiratory insufficiency which required assisted ventilation (7 mechanical ventilation for 1 day, 8 for 2 days and 2 patients on synchronized intermittent mandatory ventilation). Spirometric parameters recorded 7 to 15 days after treatment did not change from baseline values; in contrast, lung transfer factor for carbon monoxide significantly declined in a dose dependent fashion. These data confirm that rTNF alpha administered by isolation perfusion technique induces pulmonary side effects. Further studies are required to better define time course and reversibility of impairment in pulmonary function.
Villani
F
F
Divisione di Cardiologia e Fisiopatologia Respiratoria, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy.
Galimberti
M
M
Mazzola
G
G
Stifani
I
I
Persiano
L
L
Rizzi
M
M
Manzi
R
R
D000328:Adult; D000368:Aged; D010478:Chemotherapy, Cancer, Regional Perfusion; D005121:Extremities; D005260:Female; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D012509:Sarcoma / Q000188:drug therapy* / Q000556:secondary; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy; D012983:Soft Tissue Neoplasms / Q000150:complications / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects*
D014409:Tumor Necrosis Factor-alpha